Method
Level · gp.fundamentals.debt_to_revenue
Raw value 86.07% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTAxsome Therapeutics, Inc.'s latest supported as-filed period reports revenue of $218.4M, 45.5% above the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.debt_to_revenue
Raw value 86.07% · OPTIONAL
Level · gp.fundamentals.capex_revenue_ratio
Raw value 0.21% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -15.09% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 45.54% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 17.35% · OPTIONAL
Level · gp.fundamentals.operating_margin
Raw value -22.73% · CORE
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Inventory increased 105.4%; Inventory / revenue moved 506 bp higher.
2 evidence-backed componentsThis cluster groups 3 independently calculated changes: Revenue increased 45.5%; Operating margin moved 173 bp higher; Operating income decreased 35.2%.
3 evidence-backed componentsThis cluster groups 3 independently calculated changes: Revenue increased 45.5%; Operating margin moved 173 bp higher; Operating income decreased 35.2%.
3 evidence-backed componentsThis cluster groups 2 independently calculated changes: Capital expenditure changed across a low base; Capex / revenue moved 20 bp higher.
2 evidence-backed componentsInventory changed +105.4% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
AXSM · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-382277SEC ↗10-QAug 10, 2026Period Jun 30, 20260001193125-26-342360SEC ↗8-KAug 10, 2026Period Aug 10, 20260001193125-26-341206SEC ↗4Aug 7, 2026Period Aug 5, 20260001193125-26-340688SEC ↗8-KJul 15, 2026Period Jul 15, 20260001193125-26-304039SEC ↗4Jul 1, 2026Period Jul 1, 20260001193125-26-292985SEC ↗4Jun 11, 2026Period Jun 10, 20260001193125-26-268202SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Sep 3, 2026Filed Sep 3, 2026 | Jacobson Mark L.Chief Operating Officer | Option ExerciseDirect | 10,000 | $13 | $129,500 | Form 4 ↗ |
| Sep 3, 2026Filed Sep 3, 2026 | Jacobson Mark L.Chief Operating Officer | Open Market SaleDirect | 10,000 | $209 | $2.1M | Form 4 ↗ |
| Sep 3, 2026Filed Sep 3, 2026 | Jacobson Mark L.Chief Operating Officer | Option ExerciseDirect | 10,000 | $0 | $0 | Form 4 ↗ |
| Aug 6, 2026Filed Aug 7, 2026 | TABUTEAU HERRIOTChief Executive Officer | Open Market SaleDirect | 4,660 | $214 | $997,007 | Form 4 ↗ |
| Aug 6, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 21.17% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 12.43% · OPTIONAL
Revenue changed +45.5% from the comparable as-filed period.
Operating income changed -35.2% from the comparable as-filed period.
Current assets changed +22.4% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Current liabilities changed +34.6% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Selling, general & administrative changed +59.8% from the comparable as-filed period.
Trade receivables changed +39.5% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-266437| TABUTEAU HERRIOTChief Executive Officer |
| Option ExerciseDirect |
| 4,660 |
| $5 |
| $23,067 |
| Form 4 ↗ |
| Aug 6, 2026Filed Aug 7, 2026 | TABUTEAU HERRIOTChief Executive Officer | Option ExerciseDirect | 4,660 | $0 | $0 | Form 4 ↗ |
| Aug 5, 2026Filed Aug 7, 2026 | TABUTEAU HERRIOTChief Executive Officer | Option ExerciseDirect | 45,004 | $0 | $0 | Form 4 ↗ |
| Aug 5, 2026Filed Aug 7, 2026 | TABUTEAU HERRIOTChief Executive Officer | Open Market SaleDirect | 45,004 | $212 | $9.5M | Form 4 ↗ |
| Aug 5, 2026Filed Aug 7, 2026 | TABUTEAU HERRIOTChief Executive Officer | Option ExerciseDirect | 45,004 | $5 | $222,770 | Form 4 ↗ |